Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/11830
Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry
StatisticsItem usage statistics
MetadataShow Dublin Core item record
AuthorFernandez-Fabrellas, Estrella; Molina-Molina, Maria; Soriano, Joan B.; Rodriguez Portal, Jose Antonio; Ancochea, Julio; Valenzuela, Claudia; Xaubet, Antoni; Aburto Barrenetxea, M.; Alfageme Michavila, I; Bollo de Miguel, E.; Cano, E.; Casanova Espinosa, A.; Castillo Villegas, D.; Figuerola Mendal, J. A.; Garcia Sevila, R.; Gaudo Navarro, J., I; Gomez Carrera, L.; Gonzalez, J. M.; Herrera Lara, S.; Laporta Hernandez, R.; Marin Gonzalez, M.; Nieto Barbero, M. A.; Portillo, K.; Romero, A. D.; Sanchez Simon-Talero, R.; Sancho Chust, J. N.; Sellares Torres, J.; Soler Sempere, M. J.; Sauleda Roig, Jaume; Tomas Lopez, L.; Villanueva Montes, M.; SEPAR-IPF Natl Registry
Document typeresearch article
CitationFernandez-Fabrellas E, Molina-Molina M, Soriano JB, Rodriguez Portal JA, Ancochea J, Valenzuela C, et al. Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. Respir Res. 2019 Jun 17;20:127.
BackgroundLittle is known on the characteristics of patients diagnosed with idiopathic pulmonary fibrosis (IPF) in Spain. We aimed to characterize the demographic and clinical profile of IPF patients included in the IPF National Registry of the Spanish Respiratory Society (SEPAR).MethodsThis is a prospective, observational, multicentre and nationwide study that involved 608 IPF patients included in the SEPAR IPF Registry up to June 27th, 2017, and who received any treatment for their disease. IPF patients were predominantly males, ex-smokers, and aged in their 70s, similar to other registries.ResultsUpon inclusion, meanSD predicted forced vital capacity was 77.6%+/- 19.4, diffusing capacity for carbon monoxide was 48.5%+/- 17.7, and the 6-min walk distance was 423.5m +/- 110.4. The diagnosis was mainly established on results from the high-resolution computed tomography in the proper clinical context (55.0% of patients), while 21.2% of patients required invasive procedures (surgical lung biopsy) for definitive diagnosis. Anti-fibrotic treatment was prescribed in 69.4% of cases, 51.5% pirfenidone and 17.9% nintedanib, overall with a good safety profile.Conclusions The SEPAR IPF Registry should help to further characterize current characteristics and future trends of IPF patients in Spain and compare/pool them with other registries and cohorts.
MeSHAged, 80 and over
Anti-Inflammatory Agents, Non-Steroidal
Idiopathic Pulmonary Fibrosis
Persona de Mediana Edad
Antiinflamatorios no Esteroideos
Anciano de 80 o más Años
Fibrosis Pulmonar Idiopática
Sistema de Registros